HONG KONG SAR – EQS Newswire – January 22, 2024 – Uni-Bio Science Group Limited (“Uni-Bio”, the “Company”, together with its subsidiaries, the “Group”), a leading biopharmaceutical company, is pleased to announce that The China National Medical Products Administration (“NMPA”) officially approved the marketing application for BOGUTAI® (teriparatide injection) on January 16, 2024, with the approval number “国药准字S20240004”. This important milestone heralds an era of transformation in the management of orthopedic diseases and expands the choices available to patients.
BOGUTAI® represents the Group’s strategic response to the booming osteoporosis market, both globally and in China. Around 200 million people worldwide suffer from osteoporosis, with China accounting for a significant portion of this figure. The “Primary Guidelines for Diagnosis and Treatment of Osteoporosis (2022)” reveals that nearly 90 million people in China suffer from osteoporosis, and this number is expected to increase due to the aging population. Medical expenses related to major fractures due to osteoporosis in China are expected to reach a staggering RMB 132 billion by 2035 and reach RMB 163 billion by 2050.
Against the backdrop of a growing osteoporosis market, BOGUTAI® is poised to transform osteoporosis treatment for postmenopausal women at high risk of fractures. BOGUTAI® is a pioneer as the first disposable pre-filled teriparatide injection pen produced in the country. Not only does it match FORTEO in terms of efficiency, but it also surpasses it with a superior safety profile. Developed as part of a strategic partnership with Swiss personal care titan Ypsomed, BOGUTAI® features a pre-filled structure with ultra-fine needles, guaranteeing high dosing precision. This design significantly alleviates patient discomfort, thereby improving compliance. In addition, its pricing, more affordable than that of FORTEO, extends its reach to a broader patient base. This revolutionary product heralds a new era in user-friendly drug delivery, underscoring Uni-Bio’s unwavering commitment to innovation in the biopharmaceutical sector.
Uni-Bio is preparing for the launch of BOGUTAI®, a project that has been carefully prepared for over a year. The company more than doubled its sales force and orchestrated comprehensive pre-market academic promotions aimed at potential target customers. This preparatory effort demonstrates Uni-Bio’s commitment to ensuring the successful market penetration of BOGUTAI®. It also underlines the group’s ability to deliver on its promises. BOGUTAI®’s paths to success lie on the twin pillars of product differentiation and comprehensive launch preparation, marking a promising future in the osteoporosis market.
“Our experience with successful sales of GENETIME® in the bone department has provided us with invaluable information and resources that we can leverage for the commercialization of BOGUTAI®,” mentioned Mr. Kingsley Leung, President of Uni-Bio. “We are confident that our preparation, combined with our expanded commercial teams and academic promotions, will ensure the successful launch of BOGUTAI® and its market acceptance.”
Uni-Bio’s readiness is further illustrated by its substantial investment in a state-of-the-art sterile pre-filled injection production line, manufactured by the famous German brand “Bausch+Ströbel”, in Beijing. This state-of-the-art production line can produce between 3,000 and 8,000 units of cartridges per hour and up to 11,000 units of pre-filled syringes per hour. This impressive production capacity ensures that Uni-Bio is well equipped to meet long-term supply demands for BOGUTAI®.
Mr. Kingsley Leung also said: “We are incredibly proud of the investments we have made in our production facilities. These investments demonstrate our commitment to providing innovative, high-quality products to patients in need. Our production capabilities, combined with our expanded sales teams and academic promotions, position us to successfully commercialize BOGUTAI® and meet the demanding needs of the market.
Uni-Bio Science Group Limited invites potential investors and partners to join us on this exciting journey. With market approval of BOGUTAI®, the Group finds itself on the precipice of exponential growth, promising a future filled with innovative healthcare solutions and robust investment returns.
Hashtag: #UniBio
The issuer is solely responsible for the content of this announcement.
